At the time of writing, Century Therapeutics Inc [IPSC] stock is trading at $0.56, down -5.73%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IPSC shares have gain 6.11% over the last week, with a monthly amount drifted -0.99%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Century Therapeutics Inc [NASDAQ: IPSC] stock has seen the most recent analyst activity on August 08, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $6. Previously, JP Morgan downgraded its rating to Neutral on August 28, 2023, and dropped its price target to $5. On December 27, 2022, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $19 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $15 on October 31, 2022. Canaccord Genuity initiated its recommendation with a Buy and recommended $28 as its price target on October 10, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on May 23, 2022, and assigned it a price target of $27. In a note dated May 12, 2022, William Blair initiated an Mkt Perform rating.
For the past year, the stock price of Century Therapeutics Inc fluctuated between $0.34 and $1.38. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Century Therapeutics Inc [NASDAQ: IPSC] shares were valued at $0.56 at the most recent close of the market. An investor can expect a potential return of 2578.57% based on the average IPSC price forecast.
Analyzing the IPSC fundamentals
According to Century Therapeutics Inc [NASDAQ:IPSC], the company’s sales were 113.34M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.29%, Pretax Profit Margin comes in at -0.19%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.12 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5422 points at the first support level, and at 0.5266 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5861, and for the 2nd resistance point, it is at 0.6144.
Ratios To Look Out For
It is important to note that Century Therapeutics Inc [NASDAQ:IPSC] has a current ratio of 6.25. Also, the Quick Ratio is 6.25, while the Cash Ratio stands at 3.81. Considering the valuation of this stock, the price to sales ratio is 0.43, the price to book ratio is 0.27.
Transactions by insiders
Recent insider trading involved Carr Douglas, SVP Finance & Operations, that happened on Dec 08 ’25 when 257.0 shares were sold. Russotti Gregory completed a deal on Dec 08 ’25 to sell 526.0 shares. Meanwhile, Officer Pfeiffenberger Brent bought 476.0 shares on Dec 08 ’25.
